Abcuro is a technology company.
Abcuro is a technology company.
Abcuro has raised $402.0M across 3 funding rounds.
Abcuro has raised $402.0M in total across 3 funding rounds.
Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies that precisely target highly cytotoxic T cells and NK cells to treat autoimmune diseases like inclusion body myositis (IBM) and rare cancers such as T-cell large granular lymphocytic leukemia (T-LGLL). Its lead product, ulviprubart (ABC008), is an anti-KLRG1 monoclonal antibody in Phase 2/3 trials for IBM—a rare muscle-wasting disease with no approved therapies—and Phase 1/2 for T-LGLL, selectively depleting pathogenic cells while sparing healthy ones.[1][2][3][5] Abcuro serves patients with T-cell-driven autoimmune disorders and cancers where current treatments fail, addressing high unmet needs by stabilizing the immune system and halting disease progression. In February 2025, it raised $200 million in Series C funding (valuing the company at $1.2 billion) to complete its registrational MUSCLE trial, prepare a Biologics License Application, and launch commercially, signaling strong growth momentum amid biotech investor interest.[1][4]
Abcuro was founded in 2015 in Newton, Massachusetts, by Steven A. Greenberg, M.D., M.S., a clinical neurologist, Professor of Neurology at Harvard Medical School, and Brigham and Women's Hospital researcher specializing in myositis diagnostics and therapeutics.[1][5] Greenberg's work identifying cytotoxic T cells as key drivers in IBM inspired the company's precision-targeting approach, emerging from translational research on immune-mediated muscle damage where no effective treatments existed.[2][5] Early traction built around ulviprubart, with Phase 1 data presented in 2025 showing safety and pharmacodynamics for IBM at the American Academy of Neurology meeting.[1] Leadership includes biotech veteran Alex Martin as CEO, with prior exits at Palladio Biosciences and Realm Therapeutics.[5] Despite one source citing a 2020 founding in South San Francisco (likely an error given consistent 2015 evidence), Abcuro has evolved into a late-stage player, partnering with patient groups like The Myositis Association.[1][2][4][5]
Abcuro rides the wave of precision immunology and T-cell targeted therapies, a booming trend in biotech amid failures of broad immunosuppressants and rising demand for tissue-specific immunomodulators in autoimmune diseases affecting 50 million Americans.[2][5] Timing is ideal post-2025 funding, aligning with regulatory pushes for rare disease approvals (e.g., FDA's IBM incentives) and advances in antibody engineering for selective cell depletion.[1][6] Market forces favor it: exploding interest in cytotoxic T/NK modulation for "T-cell driven" orphan indications, plus oncology crossovers like lymphomas, amid a biotech funding resurgence for late-stage assets with clean safety data.[1][3][4][7] Abcuro influences the ecosystem by validating KLRG1 as a novel target, potentially expanding to dermatomyositis or solid tumors, and fostering patient advocacy integration in trials—pushing competitors toward precision over blunt-force immunosuppression.[2][5]
Abcuro's path hinges on ulviprubart's Phase 2/3 MUSCLE trial readout and BLA submission in 2026-2027, potentially making it the first IBM therapy and unlocking a $1B+ rare disease market.[1][2] Trends like AI-driven immune profiling and combination immunotherapies will accelerate its pipeline (e.g., ABC-015 into clinic), while Series C firepower supports manufacturing scale-up. Its influence could grow by pioneering T-cell precision platforms, inspiring copycats in autoimmunity-oncology overlaps and cementing Abcuro as a biotech leader in unmet immune disorders—transforming patient lives where options were once none.[1][4][6]
Abcuro has raised $402.0M in total across 3 funding rounds.
Abcuro's investors include F-Prime Capital Partners, Michele Park, New Enterprise Associates, Pontifax Venture Capital, RiverVest, Sanofi Ventures.
Abcuro has raised $402.0M across 3 funding rounds. Most recently, it raised $200.0M Series C in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $200.0M Series C | F-Prime Capital Partners, Michele Park, New Enterprise Associates, Pontifax Venture Capital, RiverVest, Sanofi Ventures | |
| Aug 1, 2023 | $160.0M Series B | Michele Park, Pontifax Venture Capital, Sanofi Ventures | |
| Jan 1, 2021 | $42.0M Series A | F-Prime Capital Partners, Pontifax Venture Capital, RiverVest, Sanofi Ventures |